Wordt geladen...
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell ly...
Bewaard in:
| Gepubliceerd in: | N Engl J Med |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4513941/ https://ncbi.nlm.nih.gov/pubmed/23782157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1306220 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|